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Usually poor ovarian response (POR) to gonadotropins reflects a diminished ovarian
reserve (DOR) that gives place to few recruitable follicles despite aggressive stimulation.
The reduction in the quantity and quality of the oocytes with advanced age is
physiological. However, some women experience DOR much earlier and become
prematurely infertile, producing an accelerated follicular depletion towards primary
ovarian insufficiency (POI). Up to now, egg donation has been commonly used to treat
their infertility. In the last thirty years, specialists in assisted reproduction have focused
their attention on the final stages of folliculogenesis, those that depend on the action of
gonadotrophins. Nevertheless, recently novel aspects have been known to act in the initial
phases, with activating and inhibiting elements. In vitro activation (IVA) combining the in
vitro stimulation of the ovarian Akt signaling pathway in ovarian cortex fragments with a
method named Hippo-signaling disruption. Later, a simplification of the technique
designated Drug-Free IVA have shown encouraging results in patients with POI.
Another innovative therapeutic option in these patients is the infusion of bone marrow-
derived stem cells (BMDSC) in order to supply an adequate ovarian niche to maintain and/
or promote follicular rescue in patients with impaired or aged ovarian reserves. In this
review, for the first time, both therapeutic options are addressed together in a common
clinical setting. The aim of this review is to analyze the physiological aspects on which
these innovative techniques are based; the preliminary results obtained up to now; and the
possible therapeutic role that they may have in the future with DOR and POI patients.
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The ovarian reserve reflects the total of ovarian follicles including
non-growing follicles (NGFs) together with those that are
growing recruited in the preantral and antral stages phases that
can finally reach ovulation. Women are born with a finite pool of
ovarian follicles that decreases dramatically during intrauterine
life from a peak of about 7 million to 1 million at birth. During
childhood the descent continues, so that at the age of menarche
about 400,000 persist follicles. Finally at menopause there are
only less than 1,000 follicles in the ovaries (1, 2). Moreover, as
follicle numbers gradually decline with age, thus a sequence of
reproductive events occurs, beginning with reduced fecundity
and natural sterility, progressing through menstrual cycle
irregularity towards a complete cessation of menstruation at
menopause. In theory, this sequence unfolds according to “fixed
time intervals” before the subsequent stage (3, 4).
According to these concepts, three different scenarios may
occur: a normal decrease of ovarian reserve with age, a lower
ovarian reserve set prenatally with an usual postnatal decay, or a
decrease of ovarian reserve during adverse postnatal
environmental or nutritional challenges (5). Anyhow, the
diminished ovarian reserve (DOR) constitutes one of the most
important therapeutic challenges in assisted reproduction, since
the ovarian response to gonadotropin stimulation is an essential
prognostic factor (2, 6, 7).
Primary ovarian insufficiency (POI) that affects 1% of women
would be the most extreme clinical manifestation of accelerated
ovarian follicular depletion and whose only available
reproductive treatment is egg donation (8). Even though
menstrual cycles cease in these patients, some of them still
contain small residual ovarian follicles.
Recently, due to new physiological knowledge in the earliest
folliculogenesis phases, attention has been focused on the
possibility of activating dormant follicles in patients with POI.
On the one hand, it has been shown that the balance between
activating (Akt stimulatory) and inhibitory pathways (Hippo-
signaling) is crucial (9). Moreover it has been demonstrated that
the manipulation of these mentioned pathways can have clinical
application, such as the disruption of the Hippo-signaling
pathway by fragmenting ovarian tissue and activating it by
incubating with Akt stimulants in primary ovarian
insufficiency patients (POI) (10–12). That technique is named
ovarian in vitro activation (IVA). Overtime, a modification of the
technique has been reported aiming to the disruption of the
Hippo-signaling pathway alone and renouncing to the chemical
activation of the ovarian tissue (Drug-Free IVA) (13–15).
On the other hand, it has been suggested that infusion of
human-derived stem cells could supply a fitting ovarian niche to
maintain or promote follicular rescue in patients with impaired
or aged ovarian reserves. Human studies propose bone marrow-
derived stem cells (BMDSC) both mesenchymal and
hematopoietic are feasible candidates to promote ovarian
rejuvenation (16, 17).
Follicular waves, quality oocytes and live births were
obtained from residual follicles with the IVA approach and
BMDSC infusion. Still, more studies are necessary to define theFrontiers in Endocrinology | www.frontiersin.org 2real role of these therapeutic options in patients with DOR
and POI.INTRAOVARIAN CONTROL OF EARLY
FOLLICULOGENESIS
Ovarian follicular reserve is conditioned by the periodic
sequence of the “activation” of primordial follicles that leave
their quiescent state. Primordial follicle activation involves
recruitment of primordial follicles into folliculogenesis for the
eventual selection of one oocyte for ovulation. When this
activation is accelerated abnormally the ovarian reserve can be
seriously affected (18).
Current strategies for controlled ovarian stimulation focus
their effect on growing follicles, whereas dormant primordial
follicles cannot be activated by known ovarian stimulation
protocols. The knowledge of the biological bases for the
awakening of the primordial follicles is essential however, up
to this point they are little known. Multiple local factors and
intracellular signaling pathways are involved. Activators such as
BMP4/7, GDF-9, KIT-ligand, FGF2/7, insulin, GREM1/2, LIF
and suppressors factors (AMH, LHX8, PTEN, Tsc1m/TORC1,
FOXO3a, YAP/Hippo-signaling, and FOXL2) have been
reported to be related to primordial follicle development (9, 19)
Most of the signaling networks and molecules involved in
primordial follicle activation have been studied using rodent
“lost-on-function” models (20, 21). Currently it is considered
that in cases of POI the depletion of ovarian reserve is produced
by an exaggerated acceleration of the activation of the pool of
primordial follicles.
The maintenance of a correct ovarian reserve will depend on a
balance between activating and inhibiting factors. In this sense,
recent studies have focused their attention on the phosphatase
and tensin homolog (PTEN)/phosphatidylinositol-3-kinase
(PI3K)/protein kinase B (AKT)/forkhead box O3 (FOXO3)
and Hippo-signaling pathway.
Although the complete mechanism of follicular activation
remains undeciphered, studies conducted in mice knockout,
have shown that the specific deletion in oocytes of the PTEN
and Foxo3 gene promote the activation and the growth of all
primordial follicles (22, 23). The PTEN gen encodes a
phosphatase enzyme that negatively regulates the PI3K-Akt-
Foxo3 signaling cascade (24, 25). It has also managed to
promote the activation of primordial follicles sleepers using
PTEN inhibitors and/or activators Akt, both in murine and
human ovaries. In the ovaries, AKT is a prominent kinase in
the PI3K/AKT/mTOR pathway and is expressed in both oocytes
and granulosa cells of human follicles (25, 26). AKT has a wide
range of substrates with both direct and indirect roles in follicle
activation (24, 25).
Coordination of cell proliferation and death is essential for
the maintenance of organ size and tissue homeostasis during
postnatal life. In mammals, the coordination of both processes is
orchestrated by Salvador/Warts/Hippo signal. This signaling
pathway consists of different regulators negative effects that act
in a cascade of kinases that in ultimately antagonizes theFebruary 2021 | Volume 11 | Article 617704
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PDZ-binding motif (TAZ) inducing a suppression of
growth (26).
YAP is inactivated by phosphorylation mediated by the Hippo
pathway, which excludes it from the nucleus, while the loss of Hippo
signaling promotes the accumulation of YAP in the nucleus and an
increase in its activity. Once inside the nucleus, the YAP protein acts
in coordination with the TAZ transcriptional activators to trigger
the expression of CCN growth factors and inhibitors of apoptosis
BIRC (baculoviral inhibitors of apoptosis repeat containing). This
results in increased proliferation and cell growth. Unlike most
activated signaling pathways by extracellular ligands, Hippo is
regulated by a network of components related to adhesion, shape
and cell polarity (27). These cellular features are mediated by rapid
changes in polymerization of the globular actin (form G) to
filamentous actin (form F) which induced by fragmenting the
tissue and which are the Hippo pathway inhibition triggers. This
way is implicated for organ size control, and recent studies provide
the theoretical basis to disrupt this pathway that can promote
follicle growth.
Studies have shown the deletion of the SAV1 or MST gen in
hepatocytes results in augmented livers in mice (28, 29). In
cardiomyocytes, deletion of SAV1 leads to enlarged hearts (30)
and Hippo-signaling is also engaged in tissue regeneration and
expansion of stem cells (31).
Based on initial observations, it has been demonstrated that
mechanical signals as ovarian fragmentation, and other forms of
ovarian injury led to actin polymerization that disrupt ovarian
Hippo-signaling, resulting in nuclear translocation of YAP.
Nuclear YAP interacts with transcriptional enhanced associate
domain (TEAD) producing transcriptional factors to increase
the expression of downstream biochemical signals (cysteine-rich
61, connective tissue growth factor and nephroblastoma
overexpressed (CNN) growth factors and baculoviral inhibitors
of apoptosis repeat containing (BIRC) apoptosis inhibitors. All
this leads to follicle growth (9, 32).
In summary, selective primordial follicles develop to the
primary stage under the control of AKT and mTOR signaling
(initial recruitment), whereas most primordial follicles remain
arrested by dormancy factors. Development of preantral and
antral follicle is restrained by the inhibitory Hippo-signaling
pathway. Therefore, correct folliculogenesis and maintenance of
the ovarian follicular reserve depend on an adequate balance
between these two routes.MECHANICAL SIGNALING IN OVARIAN
FUNCTION
Although many hormonal and molecular factors have provided
great information about the initial phases of folliculogenesis, the
role of the extracellular matrix (ECM) in these processes
remains undefined. The role of mechanobiology in the
knowledge of ovarian function and the dynamic reciprocity
that exists between ovarian cells and their microenvironment
has recently gained great interest (33, 34). It is known that whileFrontiers in Endocrinology | www.frontiersin.org 3the localization of primordial follicles in the collagen-rich
ovarian cortex offers a rigid physical environment that
supports follicle architecture and probably plays a role in their
survival, ovarian ECM rigidity limits follicular development and
therefore oocyte maturation, keeping the primordial follicles in
their quiescent stage (35). Besides, it has been shown that
growing follicles migrate to the medulla of the ovary, where
they encounter a softer, more pliant ECM, allowing its
maturation. Thus, changes in the rigidity of the ovarian ECM
have a direct effect on follicle development.
The relationship between ovarian physical environment and
its functionalism has been demonstrated in some pathological
situations, such as primary ovarian insufficiency (POI) and
polycystic ovary syndrome (PCOS).
Studies have shown that the distribution of primordial
follicles varies depending on the age of the patients. In early
ages they would be fundamentally located in the most superficial
part of the ovarian cortex. In patients with POI, the few existing
primordial follicles would be located very close to the medulla
(36). Moreover, in patients with PCOS it has been demonstrated
that all pre antral follicles are trapped in cortex which could be
explained by an aberrant Hippo-signaling, considered important
for adequate follicular growth (37).
Finally, and taking into account all of the above, a recent
study in which the remodeling of the mechanical components of
the matrisome was investigated has shown that the primordial
follicles are located in areas of the ovarian cortex rich in collagen,
conferring a rigid physical environment that supports follicle
architecture and limits follicle expansion. In addition, the
matrisome components vary depending on age and on the
different stages of follicular maturation (38).CONVENTIONAL IN VITRO ACTIVATION
(IVA) AND DRUG-FREE IVA
Mechanobiology is an emerging field of science based on
studying how physical forces and changes in the mechanical
properties of cells and tissues are able to regulate their
proliferation and differentiation. This scientific discipline
attempts to explain how mechanical forces critically regulate
cellular biochemistry and gene expression as well as tissue
development (39). This effect is established by mechanisms of
mechanotransduction. Mechanotransduction, the process by
which cells sense and respond to mechanical signals, is
mediated by extracellular matrix and cytoskeletal structures.
Hippo-signaling pathway is basic in mechanotransduction
(40, 41).
Experimental studies in mouse ovary demonstrated that using
a PTEN inhibitor and a PI3K activator for two days an increase
of FOX3 is produced in oocytes of primordial follicles, suggesting
a follicular activation. Subsequent transplantation of these
ovaries into ovariectomized hosts revealed the presence of
preovulatory follicles and mature oocytes (42). Later studies
showed that the fragmentation of the ovarian tissue produced
a polymerization of actin and a disruption of the Hippo pathway,February 2021 | Volume 11 | Article 617704
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(12, 42)
Considering these experimental studies, conventional IVA
was established combining Akt stimulators treatments, ovarian
fragmentation and autografting cortical strips by laparoscopic
surgery in POI patients (10). After ovarian stimulation, retrieval
of mature oocytes, IVF and embryo transfer, a healthy baby was
delivered. Conventional IVA was successfully used in POI
patients in Japan (11) and China (43).
Despite the encouraging results obtained with this technique,
it has been hampered by some aspects, mainly the need to
perform two laparoscopies and by the possible harmful effect
of stimulant substances (44). In this line, a recent modification of
the technique has been reported aiming to focus only on the
disruption of the Hippo-signaling pathway and avoiding the
chemical activation of the ovarian tissue (Drug-Free IVA)
(Figure 1). Fabregues et al. reported a pregnancy for the first
time using this technique (13). Another case reported a new
pregnancy with this technique (45) and in a large series only a
biopsy/scratch of the ovarian cortex was performed, observing
follicular waves in 20% of the patients (46). The largest series of
patients with POI to whom this technique was applied reported
follicle development in 50% of them with oocyte retrieval in five
of the 14 patients with four successful pregnancies with a
pregnancy rate of 57% per oocyte retrieval and 67% per
embryo transfer (14).
Furthermore, Drug-Free IVA has been used preliminarily in
POR patients based on the hypothesis that these still have
multiple residual follicles that could be activated by mechanical
stress. One recent study observed in nine of 11 patients with POR
treated with drug-free IVA, multiple growth waves and increases
in antral follicle counts were detected after ovarian stimulation
treatment. Later retrieval of mature oocytes for IVF allowed 16
embryo transfers in five patients, leading to one live birth, two
ongoing pregnancies and one miscarriage. Another patient
conceived naturally (15).Frontiers in Endocrinology | www.frontiersin.org 4In contrast, another recent study has questioned the efficacy
of Drug-Free IVA in patients with POR. In 20 patients who were
followed up for 10 weeks after the procedure, no significant
increase in AFC and AMH levels was observed. Despite this fact,
12 of these patients achieved subsequent pregnancies, which
probably reveals a limitation of the study in terms of correct
follow-up to assess long-term follicular activity after ovarian
cortical fragmentation, followed by autologous grafting under
laparoscopic surgery (47). The results achieved so far with IVA
and Drug-Free IVA are summarized in Table 1.OVARIAN NICHE CONCEPT
Researchers have studied the structure and functions of the stem
cell niche in the hematopoietic system, intestinal system,
neuronal cells, spermatogonia and the ovary system (48). The
stem cell niche is the micro-environment where the surrounding
stem cell survive, and it is composed of niche cells, matrisoma,
and cytokines. For many years it has been considered that the
aging of the organs is due to the senescence of the stem cells (49,
50). However, some authors indicate that the aging problem is
more connected with the aging of the stem cell nests (51, 52).
Specifically, in the ovary, ovarian stem cell nest is mainly
composed of granulosa cells, vascular endothelial cells,
immunologically relevant cells and molecules, surrounding the
ovarian reproductive stem cells and regulating their functions.
Ovarian germ stem cells belong to the category of adult stem cells
and most authors suggest that there are two mechanisms that
explain stem cell aging. On the one hand, endogenous aspects
that would directly affect them and, on the other, other elements
that would be more important that would focus on the
exogenous microenvironment. All this is still to be elucidated.
In other words, we know that in increasing age, ovarian
function cannot be maintained, despite the ovarian germ stem
cell activity and several experimental studies indicated thatFIGURE 1 | Comparison between Conventional IVA (top line) and Drug Free IVA (bottom line). As seen above, Drug-free IVA avoid second laparoscopy and culture
ovarian tissue. OC, ovarian cortex; ICSI, intracytoplasmic sperm injection.February 2021 | Volume 11 | Article 617704
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ovarian germ cell nests but not to the aging of the ovarian germ
stem cells (53, 54). All these concepts would serve as a basis to
propose the improvement of the niche as a method for the
rejuvenation of the ovary.ADULT STEM CELL BASED THERAPIES
TO PROMOTE FOLLICLE DEVELOPMENT
In recent years, there has been a particular interest in adult stem
cell therapy, with the potential to provide the right environment
for oocyte development from quiescent primordial follicle. In the
human body, the different organs and tissues will present a
different proportion of adult stem cells, depending on their
turnover. In tissues with high cell turnover, such as the
marrow bone or intestine, the population of stem cells is high,
and they are usually active throughout life. In this way they are
available for repair of these fabrics in great demand. There are
other tissues with cell turnover inferior, and where these stem
cells remain quiescent and are only activated in the event
of injury.
Regarding adult stem cells, research has focused on adult stem
cells of hematopoietic origin and of mesenchymal origin.
Mesenchymal stem cells (MSCs), relative to tissue cellular,
have a very high replication capacity. On the other hand, they
have the potential to differentiate themselves when they are
cultivated in vitro to other cells, such as osteocytes, adipocytes,
and chondrocytes (55, 56).
Bone marrow-derived stem cells (BMDSC) are mononuclear
cells with low immunogenicity, which makes them ideal for
therapy and transplantation. They can renew themselves, to
maintain the population of stable stem cells, but they also may
have the ability to differentiate from other tissues (adipocytes,
cartilage, etc.). These cells can migrate to other damaged tissues
and differentiate, after being induced by the release of cytokines
from damaged tissues. Yet, they liberate themselves cytokines
and growth factors, which promote anti-apoptosis andFrontiers in Endocrinology | www.frontiersin.org 5antifibrosis to restore the ovary, such as VEGF (vascular
endothelial growth factor), IGF-1, and HGF (hepatocyte
growth factor) (57). Animal studies demonstrated that BMSCs
play an important role in restoring injured ovaries in POF
induced by chemotherapy in rats (58). Moreover, they also
restore ovarian hormone production and reactivate
folliculogenesis in a mouse model of POF caused by cisplatin
(59, 60). Many researchers have studied whether is possible to
regenerate ovarian function. As it has been previously
mentioned, adult stem cells have a regenerative capacity
through paracrine release of soluble factors: e.g. cytokines,
chemokines, growth factors. Thanks to this mechanism, they
could take part in the regeneration of dysfunctional ovaries (61,
62). In fact, the soluble factors described in stem cells had already
been related to folliculogenesis in ovaries with normal function.
Among the growth factors released physiologically by stem cells
we find IGF-1, TGF-ß (Transforming growth factor ß), EGF
(Epidermal Growth Factor), and FGF1 and FGF2 (Fibroblast
Growth Factor1 and 2). FGF-2 has been associated with a
positive response to a stem cell therapy, thanks to its action on
granulosa cells (63). Given their pluripotency and low
immunogenicity, BMSCs are believed to have therapeutic
potential for POI.PRACTICAL APPLICATION OF BMDSC
THERAPIES
Clinical cases suggested the possible role of stem cells in the
recovery of ovarian function. Recovery of fertility and endocrine
function of the ovary, after bone marrow transplantation (BMT),
in patients with iatrogenic POI after chemotherapy for
malignancies has been reported. These cases describe, in
addition, spontaneous pregnancies in patients who presented
iatrogenic menopause from myeloablative chemotherapy
administered in this type of disease.
Hershlag et al. published four cases of induced early
menopause after chemotherapy or radiotherapy. All patientsTABLE 1 | Human studies involving IVA and Drug-Free IVA in POI and POR patients.







Suzuki et al., 2015
(10, 11)
IVA 37 POI 9/37 3/37 2:37
Zhai et al., 2016 (43) IVA 14 POI 6/14 1/14 1:14
Pellicer et al., 2017** – OFFA (Drug-Free
IVA)
14 POI – 3/14 3:14
Zhang et al., 2018 (46) Biopsy/Scratch 80 POI 11/80 1/80 1:80
Fàbregues et al., 2018;
Ferreri et al., 2020 (13, 14)
Drug-Free IVA 14 POI 7/14 4/14 4:14
Mahajan et al., 2019 (45) Drug-Free IVA 1 POI 1/1 – –
Kawamura et al., 2020 (15) Drug-Free IVA 11 POR 9/11* 5/11 2:11
2 ongoing
1 miscarriageFebruary 2021 | Volume 11*Patients increased AFC.
**Unofficial data are from conference presentations of stated scientist.
POI, Primary ovarian insufficiency; IVA, in vitro activation; OFFA, Ovarian fragmentation for folicular activation.| Article 617704
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autologous stem cell transplantation. Two of them with
Hodgkin’s Lymphoma and two with infiltrating ductal
carcinoma breast, which prior to treatment for their disease
conserved regular menses. After treatment, all of them started
with amenorrhea and climacteric symptoms, compatible with
POI. The authors published spontaneous pregnancies in the 4
patients after having been diagnosed with POI, probably a
consequence of autologous transplantation of stem cells (64).
Five years later, Veitia et al. reported another case, where a
woman regained fertility and achieved spontaneous pregnancy
after having been diagnosed with POI of iatrogenic cause. This
patient, with Fanconi anemia, received myeloablative
chemotherapy and radiotherapy following by an HLA-
compatible allogeneic hematopoietic transplant. Years later, it
was evidenced a return of menstruation and a spontaneous
pregnancy with subsequent birth of a premature (currently
healthy) baby. After analyzing the DNA of the baby, that of
the mother and that of the donor, it was confirmed the genetic
compatibility between the mother and the baby, ruling out the
existence of a genetic relationship between the donor and the
baby. This makes it quite unlikely that stem cells will produce a
replacement direct from the oocytes, if not through the
regeneration of the ovarian niche (65).
The first study in which the effect of BMCSD in human
ovarian tissue was analyzed as a potential treatment in patients
with POI and POR was performed by Herraiz et al. BMCSD
were obtained by apheresis after treatment with G-CSF
(granulocytic colony stimulating factor) from patients with this
diagnosis. These cells were infused in two different groups of
immunosuppressed mice, which had been reduced ovarian
reserve with different doses of chemotherapy, using more dose
to mimic patients with POI, and lower dose to mimic patients
with POR. These mice had previously undergone a xenograft
human ovarian tissue. In this population of mice, a long-term
recovery of fertility was reported, thanks to an increase in
ovarian vascularization, proliferation of cells at the level of the
ovarian and follicular stroma and a reduction of follicular
apoptosis (66).
The preliminary results obtained with the use of stem cells in
POI patients seem to depend on two aspects: the stem cells
source and the method of administration to reach the ovary.
Although adipose-derived stem cells and umbilical cord stem
cells have been used in experimental studies, those derived from
bone marrow (BMSCs) have aroused greater interest. The main
reasons are its low immunogenicity, the ease of being isolated
and amplified in vitro, and its paracrine and immunomodulatory
functions. They migrate to the site of injured tissue and
differentiate into specific cell types in the tissue under the
induction of certain factors to reconstruct the local micro-
environment. By enhancing the function of endogenous cells
and regulating the immune response, they are involved in the
repair of tissue damage, which makes BMSCs an ideal seed cell
for transplantation.
Regarding the administration techniques, human stem cells
have been infused into one or both ovaries by various methods,Frontiers in Endocrinology | www.frontiersin.org 6such as transvaginal ultrasound-guided injection (16), ovary
injection via laparoscopy intra-arterial catheterization of the
ovarian artery (67) or a combination of techniques (68, 69).
Further studies are needed to determine the most effective
approach, although less invasive methods are required for both
stem cell collection and instillation.
Gupta et al. described the birth of a live newborn in a 45-year-
old postmenopausal woman after applying this technique. They
injected the cells derived from bone marrow in the ovary by
laparoscopy, infusing them into both ovaries. This way, the
patient was exposed to two invasive techniques, in a first place
to the puncture of the iliac crest and in a second instead of
laparoscopy. After showing follicular growth in both ovaries,
they started an ovarian stimulation and with this the pregnancy
and subsequent live birth were achieved. They were the first
researchers to report a live birth after stem cell therapy in a 45-
year-old patient (67). In the same way, Edessy et al. also injected
autologous BMSCs opting for the laparoscopic approach. This
technique was carried out in 10 patients with POI, with an age
between 26 and 33 years, with continued comprehensive checks
for one year. The results, likewise, were promising, with the
return of menstruation in two patients, one pregnancy, and a
healthy live newborn (16).
Gabr et al. used autologous bone marrow mesenchymal cells
in 30 women with idiopathic POI, with a range of very broad age
between 18 and 40 years. Again, to obtain cells, a medullary
aspiration was performed from the iliac crest. In order to
introduce them into the ovary, they applied two different
techniques in two groups of patients. In the first group, the
cells were injected laparoscopically, while in a second group they
were injected by catheterization of the ovarian artery (to access
one of the two ovaries). After this technique, it was obtained a
hormonal improvement in up to 86.7% of the patients, with a
durable effect up to two years. Even though 3 patients underwent
cycles of IVF, a gestation was achieved, obtained naturally (8).
In a recent and exhaustive study Herraiz et al. evaluated the
effect of autologous stem cell ovarian transplant (ASCOT) on
ovarian reserve and IVF outcomes of POR patients. The study
consisted of BMDSC mobilization into peripheral blood by
granulocyte colony stimulating factor (G-CSF) treatment and
subsequent collection by apheresis. Cells were injected into the
ovarian artery by intra-arterial catheter in one side in such a way
that the contralateral ovary was considered as a control. ASCOT
resulted in a significant improvement in AFC two weeks after
treatment. When optimal ASCOT was considered (increase in
AFC of three or more follicles and/or two consecutive increases
of AMH levels), ovarian activity improved in 81.3% of women.
ASCOT increased the number of stimulable antral follicles and
oocytes. However, the embryo euploidy rate was low (16%). Five
pregnancies were achieved. Two after embryo transfer and three
spontaneously. Interestingly, this study evaluated soluble growth
factors after apheresis secreted by circulating BMDSC, and
positive effects were associated with the presence of fibroblast
growth factor-2 (FGF)-2 and, thrombosponding (THSP)-1.
These findings suggest that the treatment with only G-CSF
could be effective and to be valid as an alternative therapy,February 2021 | Volume 11 | Article 617704
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therefore with fewer side effects and greater safety for the patient.
In the future, the use of these stem cells should be focused on the
possibility to release soluble factors and their effect on the
ovarian niche (68).CONCLUSION
The study of the factors determining ovarian aging and the
pathophysiological mechanisms involved constitutes one of the
most interesting challenges of reproductive endocrinology.
Knowledge of activating and inhibitory pathways in the early
phases of folliculogenesis, as well as the concepts related to stem
cell niche in the ovary, represent a new therapeutic scenario in
patients with DOR and POI.
Data from animal experimentation has allowed the application
of techniques such as IVA and Drug-Free IVA in patients with
POI and DOR, reporting several live births. However, in order to
confirm these encouraging results randomized studies are needed
and therefore should still be considered experimental. The future
challenges of these techniques should be focused on predicting
which patients would be subject to treatment, since according to
the current results only 50% of patients with POI would be able to
achieve follicular waves. To know biomechanical aspects of the
ovarian tissue of these patients and also to improve aspects of theFrontiers in Endocrinology | www.frontiersin.org 7surgical technique that can make mechanotransduction
mechanisms more effective.
Future studies on the physical environment surrounding
follicles in diseased ovaries are important to design more
refined treatments. In this line, with future adaptation of
intravaginal near-infrared cameras and improvement of
IVA procedures, it would be possible to select patients
with POI and patients with DOR with residual preantral
follicles. For a better diagnosis of patients, recent advances
in in vivo imaging tools could allow monitoring primary to
secondary follicles
BMDSCs could be an alternative in ovary regeneration and
follicular development in POR or POI patients. ASCOT
approach involving the whole BMDSC population seems to be
a good approach to treat POR women. This procedure has
opened the possibility of proposing stem cell therapy simplified
by BMDSCs mobilization into blood by granulocyte colony-
stimulating factor (G-CSF) treatment avoiding laparoscopy or
intra-arterial catheterization.
These new therapeutic options might soon become a reality.AUTHOR CONTRIBUTIONS
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